Dergiler / Eurasian Journal of Medical Investigation / 2020 / Cilt: 4 - Sayı: 2

Impact of Inflammation Markers on Survival in Patients with Metastatic Colorectal Cancer

Sayfa
235–242
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Accordingly, CRP:11 mg/dL, NLR: 2.4, PLR: 137, SIII: 798, and CAR: 2.7 were determined as cut-off values for predicting OS based on theareas under the curve (AUC) in the ROC analysis (CRP: 0.742, p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This retrospective study evaluated the prognostic significance of inflammation markers (IMs) in patientswith metastatic colorectal cancer (mCRC).Methods: A total of 101 patients—44 (43.6%) were female, and 57 (56.4%) were male—were included in the study.
📊
Temel Bulgular & Veri:Cox regressionanalysis was performed for univariate and multivariate analyses, and hazard ratios (HRs) with 95% confidence intervals(CIs) were used to quantify the indices estimating the survival.Results: ROC analysis was performed to determine the optimal prognostic value of each parameter.
💡
Sonuç & Katkı:Accordingly, CRP:11 mg/dL, NLR: 2.4, PLR: 137, SIII: 798, and CAR: 2.7 were determined as cut-off values for predicting OS based on theareas under the curve (AUC) in the ROC analysis (CRP: 0.742, p
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: This retrospective study evaluated the prognostic significance of inflammation markers (IMs) in patientswith metastatic colorectal cancer (mCRC).Methods: A total of 101 patients—44 (43.6%) were female, and 57 (56.4%) were male—were included in the study. Allmedical records were reviewed retrospectively. The cut-off values for the IMs (c-reactive protein (CRP), CRP/albuminratio (CAR), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and systemic immune-inflammatoryindex (neutrophils × platelets)/lymphocytes) (SIII)) were defined by receiver operating characteristic (ROC) analysis.Overall survival (OS) was plotted using the Kaplan–Meier method and compared using the log-rank test. Cox regressionanalysis was performed for univariate and multivariate analyses, and hazard ratios (HRs) with 95% confidence intervals(CIs) were used to quantify the indices estimating the survival.Results: ROC analysis was performed to determine the optimal prognostic value of each parameter. Accordingly, CRP:11 mg/dL, NLR: 2.4, PLR: 137, SIII: 798, and CAR: 2.7 were determined as cut-off values for predicting OS based on theareas under the curve (AUC) in the ROC analysis (CRP: 0.742, p

🔖

Bu Makaleye Atıf Yap

DEMİR, T., BEŞİROĞLU, M. (2022). Impact of Inflammation Markers on Survival in Patients with Metastatic Colorectal Cancer. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 2, 235–242. https://ajindex.com/articles/508624

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1065. [CrossRef ] 2. LoNigro C, Ricci V, Vivenza D et al. Prognostic and pre¬dictive biomarkers in metastatic colorectal cancer anti- EGFR therapy. World J Gastroenterol 2016;14;22:6944–54. [CrossRef ] 3. Maru D, Venook AP, Ellis LM. Predictive Biomarkers for Bevacizumab: Are We There Yet? Clin Cancer Res 2013;19:2824–7. 4. Dogan E, Bozkurt O, Sakalar T, et al. Impact of neutrophillymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer. J BUON 2019;24:1861–1869. 5. McMillan DC. Systemic inflammation, nutritional status, and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223–6. [CrossRef ] 6. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour- associated macrophages as treatment tar¬gets in oncology. Nat Rev Clin Oncol 2017;14:399–416. [CrossRef ] 7. Grivennikov SI, Greten FR, Karin M. Immunity, inflam¬mation and cancer. Cell 2010;140:883–99. [CrossRef ] 8. Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005;189:278–82. [CrossRef ] 9. Long Y, Wang T, Gao Q, Zhou CY. Prognostic significance of pretreatment elevated platelet count in patients with colorectal cancer: a meta-analysis. Oncotarget 2016;7:81849–81861. 10. Brookman-May S, May M, Ficarra V et al. Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series. World J Urol 2013;31:1309–16. [CrossRef ] 11. Cedervall J, Hamidi A, Olsson AK. Platelets, NETs and cancer. Thromb Res 2018;164:S148–S52. [CrossRef ] 12. Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and mi¬croenvironment. Biomed Res Int 2013;2013:546318. [CrossRef ] 13. Wang X, Reyes ME, Zang D et al. EGFR signaling pro¬motes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget 2017;8:67904–67917. [CrossRef ] 14. Sevinc MM, Gunduz UR, Kinaci E et al. Preoperative neutrophil- to-lymphocyte ratio and platelet-to-lymphocyte ratio as new prognostic factors for patients wi